Notice of Closed Meeting, 51893-51894 [2021-20152]
Download as PDF
51893
Federal Register / Vol. 86, No. 178 / Friday, September 17, 2021 / Notices
the training and the driver’s response to
feedback from the actigraph.
Specifically, there are two intervention
groups: (1) Training plus actigraph
fatigue level feedback and (2) training
only with wearing actigraph but no
fatigue level feedback. The control
group will receive neither training nor
feedback on fatigue levels from their
actigraph. Participants will complete a
baseline and follow-up Work and Health
survey, sleep and activities diaries, and
sleep health knowledge questions
during each of 5 observation periods.
The Work and Health survey
administered in the first observation
period will be more comprehensive and
the abbreviated follow up Work and
Health surveys administered for the
remaining observation periods will
serve to capture only responses to
questions that can change from one
observation period to the next. Only
participants randomly selected to take
the training will complete a training
evaluation survey used to strengthen the
training’s effectiveness. Data will also be
collected from company installed in-
This project is poised to have
considerable impact in the contribution
of an evidence base for effective
interventions that could be used by
other taxi companies and drivers for
ride sourcing companies to promote
strategies in road safety.
The burden table lists that 120 of the
180 taxi drivers in the study will
complete the online training and
evaluation (approximately three hours).
All drivers (180) will complete the Work
and Health survey, and the knowledge
survey each week of the study (five
times each per participant). Each
participant will complete the sleep and
activity diary five times a day, each day
for 35 days (175 times total) which will
require approximately two minutes for
each response. There will also be three
meetings for recruitment and enrollment
(once), fitting the actigraph (weekly),
and a final meeting (weekly). The total
estimated annualized burden is
anticipated to be 2,700 hours. There are
no costs to participants other than their
time.
vehicle monitoring systems on safety
critical events (e.g., hard braking,
speeding) already collected on all
drivers as a direct measurement of
fatigue-related driving performance
events used to validate self-report data.
As part of their daily sleep and health
diaries drivers will be asked to complete
three-minute psychomotor vigilance
tests (PVTs) five times throughout the
day, to directly measure alertness using
an app installed on an electronic device.
At the end of the data collection period
the training will be offered to the
remaining study participants who will
be provided an opportunity, but no
remuneration, to complete the training
and training survey.
Study staff will use the findings from
this evaluation to improve the training
program, including content and
delivery, as well as compare fatigue
between intervention groups. Potential
impacts of this project include
improvements in work behaviors for
coping with shift work and long work
hours and an objective reduction in
fatigue compared to the control groups.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total burden
(in hours)
Type of respondents
Form name
Taxi Drivers .......................................
Online Training & Evaluation ...........
Sleep & Activities Diary ....................
Work & Health Survey .....................
Knowledge survey ............................
Recruitment & Informed Consent ....
Initial Meeting (Fit Actigraph) ...........
10-minute meeting (turn in devices,
turn in diary, receive remuneration).
120
180
180
180
180
180
180
1
175
5
5
1
5
5
3
2/60
45/60
15/60
30/60
10/60
10/60
360
1,050
675
225
90
150
150
Total ...........................................
...........................................................
........................
........................
........................
2,700
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2021–20155 Filed 9–16–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
VerDate Sep<11>2014
16:19 Sep 16, 2021
Jkt 253001
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)–
RFA–OH–20–002, Commercial Fishing
Occupational Safety Research
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
Cooperative Agreement; and RFA–OH–
20–003, Commercial Fishing
Occupational Safety Training Project
Grants.
Date: November 03, 2021.
Time: 1:00 p.m.–3:00 p.m., EDT.
Place: Video-Assisted Meeting.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Dan
Hartley, Ed.D., Scientific Review
Officer, Office of Extramural Programs,
National Institute for Occupational
Safety and Health, CDC, 1095
Willowdale Road, Morgantown, West
Virginia 26505, Telephone: (304) 285–
5812; Email: DHartley@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
E:\FR\FM\17SEN1.SGM
17SEN1
51894
Federal Register / Vol. 86, No. 178 / Friday, September 17, 2021 / Notices
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–20152 Filed 9–16–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Clinical Laboratory Improvement
Advisory Committee (CLIAC)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
for the Clinical Laboratory Improvement
Advisory Committee (CLIAC). This
meeting is open to the public, limited
only by the webcast lines available.
Check the CLIAC website on the day of
the meeting for the web conference link
www.cdc.gov/cliac.
DATES: The meeting will be held on
November 3, 2021, from 11:00 a.m. to
6:00 p.m., EDT, and November 4, 2021,
from 11:00 a.m. to 6:00 p.m., EDT.
ADDRESSES: This is a virtual meeting.
Meeting times are tentative and subject
to change. The confirmed meeting
times, agenda items, and meeting
materials including instructions for
accessing the live meeting broadcast
will be available on the CLIAC website
at www.cdc.gov/cliac.
FOR FURTHER INFORMATION CONTACT:
Nancy Anderson, MMSc, MT(ASCP),
Senior Advisor for Clinical Laboratories,
Division of Laboratory Systems, Center
for Surveillance, Epidemiology and
Laboratory Services, Office of Public
Health Scientific Services, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, Mailstop V24–3,
Atlanta, Georgia 30329–4027,
Telephone: (404) 498–2741;
NAnderson@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: This Committee is charged
with providing scientific and technical
advice and guidance to the Secretary,
HHS; the Assistant Secretary for Health;
SUMMARY:
VerDate Sep<11>2014
16:19 Sep 16, 2021
Jkt 253001
the Director, CDC; the Commissioner,
Food and Drug Administration (FDA);
and the Administrator, Centers for
Medicare and Medicaid Services (CMS).
The advice and guidance pertain to
general issues related to improvement in
clinical laboratory quality and
laboratory medicine practice and
specific questions related to possible
revision of the Clinical Laboratory
Improvement Amendments of
1988(CLIA) standards. Examples
include providing guidance on studies
designed to improve safety,
effectiveness, efficiency, timeliness,
equity, and patient-centeredness of
laboratory services; revisions to the
standards under which clinical
laboratories are regulated; the impact of
proposed revisions to the standards on
medical and laboratory practice; and the
modification of the standards and
provision of non-regulatory guidelines
to accommodate technological
advances, such as new test methods, the
electronic transmission of laboratory
information, and mechanisms to
improve the integration of public health
and clinical laboratory practices.
Matters To Be Considered: The agenda
will include agency updates from CDC,
CMS, and FDA. In addition to the
general updates, agency presentations
will include an overview of the FDA’s
Center for Biologics Evaluation and
Research, a laboratory safety update,
and a status report on the new CLIA
regulations assessment workgroup.
Presentations and CLIAC discussion
will focus on next generation
sequencing in clinical and public health
laboratories and laboratory data
exchange and harmonization. Agenda
items are subject to change as priorities
dictate.
It is the policy of CLIAC to accept
written public comments and provide a
brief period for oral public comments
pertinent to agenda items. Public
comment periods for each agenda item
are scheduled immediately prior to the
Committee discussion period for that
item. In general, each individual or
group requesting to present an oral
comment will be limited to a total time
of five minutes (unless otherwise
indicated). Speakers should email
CLIAC@cdc.gov or notify the contact
person at least five business days prior
to the meeting date. For individuals or
groups unable to attend the meeting,
CLIAC accepts written comments until
the date of the meeting (unless
otherwise stated). However, it is
requested that comments be submitted
at least five business days prior to the
meeting date so that the comments may
be made available to the Committee for
their consideration and public
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
distribution. All written comments will
be included in the meeting Summary
Report posted on the CLIAC website.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–20151 Filed 9–16–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–21–1274; Docket No. CDC–2021–
0096]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on the
Million Hearts Hospital & Health
System Recognition Program. This
program recognizes institutions working
systematically to improve the
cardiovascular health of the population
and communities they serve.
DATES: CDC must receive written
comments on or before November 16,
2021.
SUMMARY:
You may submit comments,
identified by Docket No. CDC–2021–
0096 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
ADDRESSES:
E:\FR\FM\17SEN1.SGM
17SEN1
Agencies
[Federal Register Volume 86, Number 178 (Friday, September 17, 2021)]
[Notices]
[Pages 51893-51894]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-20152]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Strategic
Business Initiatives Unit, Office of the Chief Operating Officer, CDC,
pursuant to Public Law 92-463. The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)- RFA-OH-20-002, Commercial Fishing
Occupational Safety Research Cooperative Agreement; and RFA-OH-20-003,
Commercial Fishing Occupational Safety Training Project Grants.
Date: November 03, 2021.
Time: 1:00 p.m.-3:00 p.m., EDT.
Place: Video-Assisted Meeting.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Dan Hartley, Ed.D., Scientific
Review Officer, Office of Extramural Programs, National Institute for
Occupational Safety and Health, CDC, 1095 Willowdale Road, Morgantown,
West Virginia 26505, Telephone: (304) 285-5812; Email:
[email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been
[[Page 51894]]
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-20152 Filed 9-16-21; 8:45 am]
BILLING CODE 4163-18-P